000153797 001__ 153797
000153797 005__ 20240229123050.0
000153797 0247_ $$2doi$$a10.1053/j.gastro.2020.02.029
000153797 0247_ $$2pmid$$apmid:32088204
000153797 0247_ $$2ISSN$$a0016-5085
000153797 0247_ $$2ISSN$$a1528-0012
000153797 0247_ $$2altmetric$$aaltmetric:76599501
000153797 037__ $$aDKFZ-2020-00463
000153797 041__ $$aeng
000153797 082__ $$a610
000153797 1001_ $$aPhipps, Amanda I$$b0
000153797 245__ $$aAssociation Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies.
000153797 260__ $$aPhiladelphia, Pa. [u.a.]$$bSaunders$$c2020
000153797 3367_ $$2DRIVER$$aarticle
000153797 3367_ $$2DataCite$$aOutput Types/Journal article
000153797 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683884804_20085
000153797 3367_ $$2BibTeX$$aARTICLE
000153797 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153797 3367_ $$00$$2EndNote$$aJournal Article
000153797 500__ $$a2020 Jun;158(8):2158-2168.e4 / #EA:C070#LA:C070#
000153797 520__ $$aThe heterogeneity among colorectal tumors is probably due to differences in developmental pathways and might associate with patient survival times. We studied the relationship among markers of different subtypes of colorectal tumors and patient survival.We pooled data from 7 observational studies, comprising 5010 patients with colorectal cancer. All the studies collected information on microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and mutations in KRAS and BRAF in tumors. Tumors with complete marker data were classified as type 1 (MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS), type 2 (not MSI high, CIMP positive, with pathogenic mutations in BRAF but not KRAS); type 3 (not MSI high or CIMP, with pathogenic mutations in KRAS but not BRAF); type 4 (not MSI-high or CIMP, no pathogenic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BRAF or KRAS). We used Cox regression to estimate hazard ratios (HR) and 95% CIs for associations of these subtypes and tumor markers with disease-specific survival (DSS) and overall survival (OS) times, adjusting for age, sex, stage at diagnosis, and study population.Patients with type 2 colorectal tumors had significantly longer time of DSS than patients with type 4 tumors (HRDSS, 1.66; 95% CI, 1.33-2.07), regardless of sex, age, or stage at diagnosis. Patients without MSI-high tumors had significantly shorter time of DSS compared to patients with MSI-high tumors (HRDSS, 0.42; 95% CI, 0.27-0.64), regardless of other tumor markers or stage, or patient sex or age.In a pooled analysis of data from 7 observational studies of patients with colorectal cancer, we found that tumor subtypes, defined by combinations of 4 common tumor markers, were associated with differences in survival time. Colorectal tumor subtypes might therefore be used in determining patients' prognoses.
000153797 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153797 588__ $$aDataset connected to CrossRef, PubMed,
000153797 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b1$$eFirst author
000153797 7001_ $$aHarrison, Tabitha$$b2
000153797 7001_ $$aBanbury, Barbara$$b3
000153797 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4
000153797 7001_ $$aCampbell, Peter T$$b5
000153797 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b6
000153797 7001_ $$aBuchanan, Daniel$$b7
000153797 7001_ $$aChan, Andrew T$$b8
000153797 7001_ $$aFarris, Alton B$$b9
000153797 7001_ $$aFigueiredo, Jane C$$b10
000153797 7001_ $$aGallinger, Steven$$b11
000153797 7001_ $$aGiles, Graham G$$b12
000153797 7001_ $$aJenkins, Mark$$b13
000153797 7001_ $$aMilne, Roger L$$b14
000153797 7001_ $$aNewcomb, Polly A$$b15
000153797 7001_ $$aSlattery, Martha L$$b16
000153797 7001_ $$aSong, Mingyang$$b17
000153797 7001_ $$aOgino, Shuji$$b18
000153797 7001_ $$aZaidi, Syed H$$b19
000153797 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b20$$eLast author
000153797 7001_ $$aPeters, Ulrike$$b21
000153797 773__ $$0PERI:(DE-600)1478699-0$$a10.1053/j.gastro.2020.02.029$$gp. S0016508520302407$$n8$$p2158-2168.e4$$tGastroenterology$$v158$$x0016-5085$$y2020
000153797 909CO $$ooai:inrepo02.dkfz.de:153797$$pVDB
000153797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000153797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000153797 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000153797 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153797 9141_ $$y2020
000153797 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGASTROENTEROLOGY : 2017
000153797 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153797 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153797 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153797 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153797 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153797 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153797 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153797 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153797 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153797 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153797 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bGASTROENTEROLOGY : 2017
000153797 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153797 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000153797 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000153797 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000153797 980__ $$ajournal
000153797 980__ $$aVDB
000153797 980__ $$aI:(DE-He78)C070-20160331
000153797 980__ $$aI:(DE-He78)C120-20160331
000153797 980__ $$aI:(DE-He78)HD01-20160331
000153797 980__ $$aI:(DE-He78)C020-20160331
000153797 980__ $$aUNRESTRICTED